−0.20 INR
−26.72 M INR
132.05 M INR
About ASPIRA PATHLAB & DIAGNOSTICS L
Sector
Industry
CEO
Pankaj J. Shah
Website
Headquarters
Mumbai
Founded
1973
ISIN
INE500C01017
FIGI
BBG00CSQHLY3
Aspira Pathlab & Diagnostics Ltd. engages in the operation of diagnostic centers and laboratories. The firm involves in the pathological investigations of bio-chemistry, hematology, histopathology, microbiology, immune-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its services includes on-site and off-site evaluation of employee's health; on-site industry specific fast screening tests; management of employee data ensuring complete data security and privacy; and customized packages as per industry needs. The company was founded on July 3, 1973 and is headquartered in Navi Mumbai, India.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ASPIRA is 61.20 INR — it hasn't changed in the past 24 hours. Watch ASPIRA PATHLAB & DIAGNOSTICS L stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange ASPIRA PATHLAB & DIAGNOSTICS L stocks are traded under the ticker ASPIRA.
ASPIRA stock has fallen by −5.85% compared to the previous week, the month change is a −0.49% fall, over the last year ASPIRA PATHLAB & DIAGNOSTICS L has showed a 56.20% increase.
ASPIRA reached its all-time high on Nov 12, 2021 with the price of 124.15 INR, and its all-time low was 14.15 INR and was reached on Feb 28, 2018. View more price dynamics on ASPIRA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ASPIRA stock is 0.00% volatile and has beta coefficient of 0.12. Track ASPIRA PATHLAB & DIAGNOSTICS L stock price on the chart and check out the list of the most volatile stocks — is ASPIRA PATHLAB & DIAGNOSTICS L there?
Today ASPIRA PATHLAB & DIAGNOSTICS L has the market capitalization of 629.93 M, it has decreased by −5.48% over the last week.
Yes, you can track ASPIRA PATHLAB & DIAGNOSTICS L financials in yearly and quarterly reports right on TradingView.
ASPIRA net income for the last quarter is 9.90 M INR, while the quarter before that showed 471.00 K INR of net income which accounts for 2.00 K% change. Track more ASPIRA PATHLAB & DIAGNOSTICS L financial stats to get the full picture.
No, ASPIRA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 115.00 employees. See our rating of the largest employees — is ASPIRA PATHLAB & DIAGNOSTICS L on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ASPIRA PATHLAB & DIAGNOSTICS L EBITDA is 12.16 M INR, and current EBITDA margin is −8.99%. See more stats in ASPIRA PATHLAB & DIAGNOSTICS L financial statements.
Like other stocks, ASPIRA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ASPIRA PATHLAB & DIAGNOSTICS L stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ASPIRA PATHLAB & DIAGNOSTICS L technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ASPIRA PATHLAB & DIAGNOSTICS L stock shows the buy signal. See more of ASPIRA PATHLAB & DIAGNOSTICS L technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.